<table id="i36111d47-3a95-4c22-8350-40c35f47506b" width="639" xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<caption>
                Table 9. Established and Other Potentially Significant Drug
                Interactions
              </caption>
<col width="26%"></col>
<col width="22%"></col>
<col width="51%"></col>
<thead>
<tr>
<td>
<content stylecode="bold">Concomitant Drug Class:</content>
<br/>
<content stylecode="bold">Drug Name</content>
</td>
<td>
<content stylecode="bold">
                      Effect on Concentration of Lopinavir or Concomitant
                      Drug
                    </content>
</td>
<td>
<content stylecode="bold">Clinical Comment </content>
</td>
</tr>
</thead>
<tbody>
<tr>
<td>
<paragraph>
                      *   <content stylecode="italics">
                        see Clinical Pharmacology (<linkhtml href="#section_12.3">12.3</linkhtml>)
                      </content> for Magnitude of Interaction.
                    </paragraph>
</td>
</tr>
<tr>
<td>
<content stylecode="italics">
<content stylecode="bold">
                        HIV-1 Antiviral
                        Agents
                      </content>
</content>
</td>
</tr>
<tr>
<td>
                    Non-nucleoside Reverse Transcriptase
                    Inhibitors:<br/>efavirenz*,<br/>nevirapine*
                  </td>
<td>↓ lopinavir</td>
<td>
                    KALETRA dose increase is recommended in all patients <content stylecode="italics">
                      [see Dosage and Administration (<linkhtml href="#section_2.1">2.1</linkhtml>)
                      and Clinical Pharmacology (<linkhtml href="#section_12.3">12.3</linkhtml>)]
                    </content>.<br/>Increasing the dose of KALETRA
                    tablets to 500/125 mg (given as two 200/50 mg tablets and one 100/25 mg tablet)
                    twice daily co-administered with efavirenz resulted in similar lopinavir
                    concentrations compared to KALETRA tablets 400/100 mg (given as two 200/50 mg
                    tablets) twice daily without efavirenz.<br/>Increasing the dose of KALETRA
                    tablets to 600/150 mg (given as three 200/50 mg tablets) twice daily
                    co-administered with efavirenz resulted in significantly higher lopinavir plasma
                    concentrations compared to KALETRA tablets 400/100 mg twice daily without
                    efavirenz. <br/>KALETRA should not be administered once daily in combination with
                    efavirenz or nevirapine<br/>
<content stylecode="italics">
                      [see Dosage and Administration
                      (<linkhtml href="#section_2.1">2.1</linkhtml>) and Clinical Pharmacology (<linkhtml href="#section_12.3">12.3</linkhtml>)]
                    </content>.
                  </td>
</tr>
<tr>
<td>
                    Non-nucleoside Reverse Transcriptase Inhibitor:<br/>delavirdine
                  </td>
<td>↑ lopinavir</td>
<td>
                    Appropriate doses of the combination with respect to safety and efficacy
                    have not been established.
                  </td>
</tr>
<tr>
<td>
                    Nucleoside Reverse Transcriptase Inhibitor:<br/>didanosine
                  </td>
<td>
<br/>
</td>
<td>
                    KALETRA tablets can be administered simultaneously with didanosine without
                    food.<br/>For KALETRA oral solution, it is recommended that didanosine be
                    administered on an empty stomach; therefore, didanosine should be given one hour
                    before or two hours after KALETRA oral solution (given with food).
                  </td>
</tr>
<tr>
<td>
                    Nucleoside Reverse Transcriptase Inhibitor:<br/>tenofovir
                  </td>
<td>↑ tenofovir</td>
<td>
                    KALETRA increases tenofovir concentrations. The mechanism of this
                    interaction is unknown. Patients receiving KALETRA and tenofovir should be
                    monitored for adverse reactions associated with tenofovir.
                  </td>
</tr>
<tr>
<td>
                    Nucleoside Reverse Transcriptase Inhibitor:<br/>abacavir<br/>zidovudine
                  </td>
<td>
                    ↓ abacavir<br/>↓ zidovudine
                  </td>
<td>
                    KALETRA induces glucuronidation; therefore, KALETRA has the potential to
                    reduce zidovudine and abacavir plasma concentrations. The clinical significance
                    of this potential interaction is unknown.
                  </td>
</tr>
<tr>
<td>
                    HIV-1 Protease Inhibitor:<br/>amprenavir*
                  </td>
<td>
                    ↑ amprenavir <br/>↓ lopinavir
                  </td>
<td>
                    KALETRA should not be administered once daily in combination with amprenavir
                    <br/>
<content stylecode="italics">
                      [see Dosage and Administration (<linkhtml href="#section_2.1">2.1</linkhtml>)]
                    </content>.
                  </td>
</tr>
<tr>
<td>
                    HIV-1 Protease Inhibitor:<br/>fosamprenavir/ritonavir
                  </td>
<td>
                    ↓ amprenavir <br/>↓ lopinavir
                  </td>
<td>
                    An increased rate of adverse reactions has been observed with
                    co-administration of these medications. Appropriate doses of the combinations
                    with respect to safety and efficacy have not been established.
                  </td>
</tr>
<tr>
<td>
                    HIV-1 Protease Inhibitor:<br/>indinavir*
                  </td>
<td>↑ indinavir </td>
<td>
                    Decrease indinavir dose to 600 mg twice daily, when co-administered with
                    KALETRA 400/100 mg twice daily <content stylecode="italics">
                      [see Clinical Pharmacology
                      (<linkhtml href="#section_12.3">12.3</linkhtml>)]
                    </content>. KALETRA once daily has not been
                    studied in combination with indinavir.
                  </td>
</tr>
<tr>
<td>
                    HIV-1 Protease Inhibitor:<br/>nelfinavir*
                  </td>
<td>
                    ↑ nelfinavir <br/>↑ M8 metabolite of nelfinavir<br/>↓ lopinavir
                  </td>
<td>
                    KALETRA should not be administered once daily in combination with
                    nelfinavir<br/>
<content stylecode="italics">
                      [see Dosage and Administration (<linkhtml href="#section_2.1">2.1</linkhtml>) and Clinical Pharmacology (<linkhtml href="#section_12.3">12.3</linkhtml>)]
                    </content>.<br/>
<br/>
</td>
</tr>
<tr>
<td>
                    HIV-1 Protease Inhibitor:<br/>ritonavir*
                  </td>
<td>↑ lopinavir</td>
<td>
                    Appropriate doses of additional ritonavir in combination with KALETRA with
                    respect to safety and efficacy have not been established.
                  </td>
</tr>
<tr>
<td>
                    HIV-1 Protease Inhibitor:<br/>saquinavir*
                  </td>
<td>↑ saquinavir </td>
<td>
                    The saquinavir dose is 1000 mg twice daily, when co-administered with
                    KALETRA 400/100 mg twice daily. <br/>KALETRA once daily has not been studied in
                    combination with saquinavir.
                  </td>
</tr>
<tr>
<td>
                    HIV-1 Protease Inhibitor:<br/>tipranavir
                  </td>
<td>
                    ↓ lopinavir AUC and C<sub>min</sub>
</td>
<td>
                    KALETRA should not be administered with tipranavir (500 mg twice daily)
                    co-administered with ritonavir (200 mg twice daily).
                  </td>
</tr>
<tr>
<td>HIV CCR5 – antagonist: maraviroc</td>
<td>↑ maraviroc</td>
<td>
                    Concurrent administration of maraviroc with KALETRA will increase plasma
                    levels of maraviroc. When co-administered, patients should receive 150 mg twice
                    daily of maraviroc. For further details see complete prescribing information for
                    Selzentry<sup>®</sup> (maraviroc).
                  </td>
</tr>
<tr>
<td>
<content stylecode="italics">
<content stylecode="bold">
                        Other
                        Agents
                      </content>
</content>
</td>
</tr>
<tr>
<td>
                    Antiarrhythmics:<br/>amiodarone,<br/>bepridil,<br/>lidocaine (systemic),
                    and<br/>quinidine
                  </td>
<td>↑ antiarrhythmics</td>
<td>
                    Caution is warranted and therapeutic concentration monitoring (if available)
                    is recommended for antiarrhythmics when co-administered with KALETRA.
                  </td>
</tr>
<tr>
<td>
                    Anticancer Agents: <br/>vincristine,<br/>vinblastine,<br/>dasatinib,
                    <br/>nilotinib
                  </td>
<td>↑ anticancer agents</td>
<td>
                    Concentrations of these drugs may be increased when co-administered with
                    KALETRA resulting in the potential for increased adverse events usually
                    associated with these anticancer agents. <br/>For vincristine and vinblastine,
                    consideration should be given to temporarily withholding the
                    ritonavir-containing antiretroviral regimen in patients who develop significant
                    hematologic or gastrointestinal side effects when KALETRA is administered
                    concurrently with vincristine or vinblastine. If the antiretroviral regimen must
                    be withheld for a prolonged period, consideration should be given to initiating
                    a revised regimen that does not include a CYP3A or P-gp inhibitor.<br/>A decrease
                    in the dosage or an adjustment of the dosing interval of nilotinib and dasatinib
                    may be necessary for patients requiring co-administration with strong CYP3A
                    inhibitors such as KALETRA. Please refer to the nilotinib and dasatinib
                    prescribing information for dosing instructions.
                  </td>
</tr>
<tr>
<td>
                    Anticoagulant:<br/>warfarin
                  </td>
<td>
<br/>
</td>
<td>
                    Concentrations of warfarin may be affected. It is recommended that INR
                    (international normalized ratio) be monitored.
                  </td>
</tr>
<tr>
<td>
                    Anticonvulsants:<br/>carbamazepine,<br/>phenobarbital,<br/>phenytoin
                  </td>
<td>
                    ↓ lopinavir<br/>↓ phenytoin
                  </td>
<td>
                    KALETRA may be less effective due to decreased lopinavir plasma
                    concentrations in patients taking these agents concomitantly and should be used
                    with caution.<br/>KALETRA should not be administered once daily in combination
                    with carbamazepine, phenobarbital, or phenytoin.<br/>
<br/>In addition,
                    co-administration of phenytoin and KALETRA may cause decreases in steady-state
                    phenytoin concentrations. Phenytoin levels should be monitored when
                    co-administering with KALETRA.
                  </td>
</tr>
<tr>
<td>
                    Antidepressant: <br/>bupropion
                  </td>
<td>
                    ↓ bupropion<br/>↓ active metabolite, <br/>hydroxybupropion
                  </td>
<td>
                    Concurrent administration of bupropion with KALETRA may decrease plasma
                    levels of both bupropion and its active metabolite (hydroxybupropion). Patients
                    receiving KALETRA and bupropion concurrently should be monitored for an adequate
                    clinical response to bupropion.
                  </td>
</tr>
<tr>
<td>
                    Antidepressant:<br/>trazodone<br/>
</td>
<td>↑ trazodone</td>
<td>
                    Concomitant use of trazodone and KALETRA may increase concentrations of
                    trazodone. Adverse reactions of nausea, dizziness, hypotension and syncope have
                    been observed following co-administration of trazodone and ritonavir. If
                    trazodone is used with a CYP3A4 inhibitor such as ritonavir, the combination
                    should be used with caution and a lower dose of trazodone should be
                    considered.
                  </td>
</tr>
<tr>
<td>
                    Anti-infective:<br/>clarithromycin
                  </td>
<td>↑ clarithromycin</td>
<td>
                    For patients with renal impairment, the following dosage adjustments should
                    be considered:
                    <list id="i70858d73-3a41-4573-801e-b5821d1dc81e" listtype="unordered">
<item>
                        For patients with CL<sub>CR</sub> 30 to 60 mL/min the dose of
                        clarithromycin should be reduced by 50%.
                      </item>
<item>
                        For patients with CL<sub>CR</sub> greater then  30 mL/min the dose of
                        clarithromycin should be decreased by 75%.
                      </item>
</list>
<br/>No dose adjustment for
                    patients with normal renal function is necessary.
                  </td>
</tr>
<tr>
<td>
                    Antifungals:<br/>ketoconazole*,<br/>itraconazole,<br/>voriconazole
                  </td>
<td>
                    ↑ ketoconazole<br/>↑ itraconazole<br/>↓ voriconazole
                  </td>
<td>
                    High doses of ketoconazole (less then 200 mg/day) or itraconazole
                    (less then 200 mg/day) are not recommended. <br/>Co-administration of voriconazole
                    with KALETRA has not been studied. However, a study has been shown that
                    administration of voriconazole with ritonavir 100 mg every 12 hours decreased
                    voriconazole steady-state AUC by an average of 39%; therefore, co-administration
                    of KALETRA and voriconazole may result in decreased voriconazole concentrations
                    and the potential for decreased voriconazole effectiveness and should be
                    avoided, unless an assessment of the benefit/risk to the patient justifies the
                    use of voriconazole. Otherwise, alternative antifungal therapies should be
                    considered in these patients.
                  </td>
</tr>
<tr>
<td>
                    Anti-gout: <br/>colchicine
                  </td>
<td>↑ colchicine</td>
<td>
                    Patients with renal or hepatic impairment should not be given colchicine
                    with KALETRA.
                    <br/>
<content stylecode="underline">
                      Treatment of gout
                      flares-co-administration of colchicine in patients on KALETRA:
                    </content>
<br/>0.6 mg (1 tablet) x 1 dose, followed by 0.3 mg (half tablet) 1 hour
                    later. Dose to be repeated no earlier than 3 days.
                    <br/>
<content stylecode="underline">
                      Prophylaxis of gout flares-co-administration of
                      colchicine in patients on KALETRA:
                    </content>
<br/>If the original colchicine regimen was 0.6 mg twice a day, the
                    regimen should be adjusted to 0.3 mg once a day.
                    <br/>If the original colchicine regimen was 0.6 mg once a day, the regimen
                    should be adjusted to 0.3 mg once every other day.
                    <br/>
<content stylecode="underline">
                      Treatment of familial Mediterranean fever
                      (FMF)-co-administration of colchicine in patients on KALETRA:
                    </content>
<br/>Maximum daily dose of 0.6 mg (may be given as 0.3 mg twice a
                    day).
                  </td>
</tr>
<tr>
<td>
                    Antimycobacterial:<br/>rifabutin*
                  </td>
<td>↑ rifabutin and rifabutin metabolite</td>
<td>
                    Dosage reduction of rifabutin by at least 75% of the usual dose of 300
                    mg/day is recommended (i.e., a maximum dose of 150 mg every other day or three
                    times per week). Increased monitoring for adverse reactions is warranted in
                    patients receiving the combination. Further dosage reduction of rifabutin may be
                    necessary.
                  </td>
</tr>
<tr>
<td>
                    Antimycobacterial:<br/>rifampin
                  </td>
<td>↓ lopinavir</td>
<td>
                    May lead to loss of virologic response and possible resistance to KALETRA or
                    to the class of protease inhibitors or other co-administered antiretroviral
                    agents. A study evaluated combination of rifampin 600 mg once daily, with
                    KALETRA 800/200 mg twice daily or KALETRA 400/100 mg + ritonavir 300 mg twice
                    daily. Pharmacokinetic and safety results from this study do not allow for a
                    dose recommendation. Nine subjects (28%) experienced a ≥ grade 2 increase in
                    ALT/AST, of which seven (21%) prematurely discontinued study per protocol. Based
                    on the study design, it is not possible to determine whether the frequency or
                    magnitude of the ALT/AST elevations observed is higher than what would be seen
                    with rifampin alone <content stylecode="italics">
                      [see Clinical Pharmacology (<linkhtml href="#section_12.3">12.3</linkhtml>) for magnitude of interaction]
                    </content>.
                  </td>
</tr>
<tr>
<td>
                    Antiparasitic:<br/>atovaquone
                  </td>
<td>↓ atovaquone</td>
<td>
                    Clinical significance is unknown; however, increase in atovaquone doses may
                    be needed.
                  </td>
</tr>
<tr>
<td>Benzodiazepines: parenterally administered midazolam</td>
<td>↑ midazolam</td>
<td>
                    Midazolam is extensively metabolized by CYP3A4. Increases in the
                    concentration of midazolam are expected to be significantly higher with oral
                    than parenteral administration. Therefore, KALETRA should not be given with
                    orally administered midazolam <content stylecode="italics">
                      [see Contraindications (<linkhtml href="#section_4">4</linkhtml>)]
                    </content>. If KALETRA is coadministered with parenteral
                    midazolam, close clinical monitoring for respiratory depression and/or prolonged
                    sedation should be exercised and dosage adjustment should be
                    considered.
                  </td>
</tr>
<tr>
<td>
                    Calcium Channel Blockers, dihydropyridine:<br/>e.g.,
                    felodipine,<br/>nifedipine,<br/>nicardipine
                  </td>
<td>↑ dihydropyridine calcium channel blockers</td>
<td>
                    Caution is warranted and clinical monitoring of patients is
                    recommended.
                  </td>
</tr>
<tr>
<td>
                    Contraceptive:<br/>ethinyl estradiol*
                  </td>
<td>↓ ethinyl estradiol</td>
<td>
                    Because contraceptive steroid concentrations may be altered when KALETRA is
                    co-administered with oral contraceptives or with the contraceptive patch,
                    alternative methods of nonhormonal contraception are recommended.
                  </td>
</tr>
<tr>
<td>
                    Corticosteroid:<br/>dexamethasone<br/>
<br/>
</td>
<td>↓ lopinavir</td>
<td>
                    Use with caution. KALETRA may be less effective due to decreased lopinavir
                    plasma concentrations in patients taking these agents
                    concomitantly.<br/>
<br/>
<br/>
</td>
</tr>
<tr>
<td>disulfiram/metronidazole</td>
<td>
<br/>
</td>
<td>
<paragraph>
                      KALETRA oral solution contains alcohol, which can produce
                      disulfiram-like reactions when co-administered with disulfiram or other drugs
                      that produce this reaction (e.g., metronidazole).
                    </paragraph>
</td>
</tr>
<tr>
<td>
                    Endothelin receptor antagonists: <br/>bosentan
                  </td>
<td>↑ bosentan</td>
<td>
<content stylecode="underline">
                      Co-administration of bosentan in patients on
                      KALETRA:
                    </content>
<br/>In patients who have been receiving KALETRA for at least
                    10 days, start bosentan at 62.5 mg once daily or every other day based upon
                    individual tolerability.
                    <br/>
<content stylecode="underline">
                      Co-administration of KALETRA in patients on
                      bosentan:
                    </content>
<br/>Discontinue use of bosentan at least 36 hours prior to initiation of
                    KALETRA.
                    <br/>After at least 10 days following the initiation of KALETRA, resume
                    bosentan at 62.5 mg once daily or every other day based upon individual
                    tolerability.
                  </td>
</tr>
<tr>
<td>
                    HMG-CoA Reductase Inhibitors:<br/>atorvastatin<br/>rosuvastatin
                  </td>
<td>
                    ↑ atorvastatin<br/>↑ rosuvastatin
                  </td>
<td>
                    Use lowest possible dose of atorvastatin or rosuvastatin with careful
                    monitoring, or consider other HMG-CoA reductase inhibitors such as pravastatin
                    or fluvastatin in combination with KALETRA.
                  </td>
</tr>
<tr>
<td>
                    Immunosuppressants:<br/>cyclosporine,<br/>tacrolimus,<br/>rapamycin
                  </td>
<td>↑ immunosuppressants</td>
<td>
                    Therapeutic concentration monitoring is recommended for immunosuppressant
                    agents when co-administered with KALETRA.
                  </td>
</tr>
<tr>
<td>
                    Inhaled Steroid:<br/>fluticasone
                  </td>
<td>↑ fluticasone</td>
<td>
                    Concomitant use of fluticasone propionate and KALETRA may increase plasma
                    concentrations of fluticasone propionate, resulting in significantly reduced
                    serum cortisol concentrations. Systemic corticosteroid effects including
                    Cushing's syndrome and adrenal suppression have been reported during
                    post-marketing use in patients receiving ritonavir and inhaled or intranasally
                    administered fluticasone propionate. Co-administration of fluticasone propionate
                    and KALETRA is not recommended unless the potential benefit to the patient
                    outweighs the risk of systemic corticosteroid side effect.
                  </td>
</tr>
<tr>
<td>
                    Long-acting beta-adrenoceptor agonist: <br/>salmeterol
                  </td>
<td>↑ salmeterol</td>
<td>
                    Concurrent administration of salmeterol and KALETRA is not recommended. The
                    combination may result in increased risk of cardiovascular adverse events
                    associated with salmeterol, including QT prolongation, palpitations and sinus
                    tachycardia.
                  </td>
</tr>
<tr>
<td>
                    Narcotic Analgesic:<br/>methadone*<br/>fentanyl
                  </td>
<td>
                    ↓ methadone<br/>↑ fentanyl
                  </td>
<td>
                    Dosage of methadone may need to be increased when co-administered with
                    KALETRA.<br/>Concentrations of fentanyl are expected to increase. Careful
                    monitoring of therapeutic and adverse effects (including potentially fatal
                    respiratory depression) is recommended when fentanyl is concomitantly
                    administered with KALETRA.
                  </td>
</tr>
<tr>
<td>
                    PDE5 inhibitors: <br/>sildenafil, <br/>tadalafil, <br/>vardenafil
                  </td>
<td>
                    ↑ sildenafil <br/>↑ tadalafil <br/>↑ vardenafil
                  </td>
<td>
                    Particular caution should be used when prescribing sildenafil, tadalafil, or
                    vardenafil in patients receiving KALETRA. Co-administration of KALETRA with
                    these drugs is expected to substantially increase their concentrations and may
                    result in an increase in PDE5 inhibitor associated adverse reactions including
                    hypotension, syncope, visual changes and prolonged erection.
                    <br/>Use of PDE5 inhibitors for pulmonary arterial
                    hypertension (PAH):
                    <br/>Sildenafil (Revatio<sup>®</sup>) is contraindicated when
                    used for the treatment of pulmonary arterial hypertension (PAH) because a safe
                    and effective dose has not been established when used with KALETRA <content stylecode="italics">
                      [see Contraindications (<linkhtml href="#section_4">4</linkhtml>)]
                    </content>.
                    <br/>The following dose adjustments are recommended for use of tadalafil
                    (Adcirca<sup>®</sup>) with KALETRA:
                    <br/>
<content stylecode="underline">
                      Co-administration of ADCIRCA in patients on
                      KALETRA:
                    </content>
<br/>In patients receiving KALETRA for at least one week, start ADCIRCA at
                    20 mg once daily. Increase to 40 mg once daily based upon individual
                    tolerability.
                    <br/>
<content stylecode="underline">
                      Co-administration of KALETRA in patients on
                      ADCIRCA:
                    </content>
<br/>Avoid use of ADCIRCA during the initiation of KALETRA. Stop ADCIRCA
                    at least 24 hours prior to starting KALETRA. After at least one week following
                    the initiation of KALETRA, resume ADCIRCA at 20 mg once daily. Increase to 40 mg
                    once daily based upon individual tolerability.
                    <br/>Use of PDE5 inhibitors for erectile dysfunction: <br/>
<br/>It is
                    recommended not to exceed the following doses:
                    <list id="i769ec77b-99d3-46b0-8787-da3468f52163" listtype="unordered">
<item>Sildenafil: 25 mg every 48 hours</item>
<item>Tadalafil: 10 mg every 72 hours</item>
<item>Vardenafil: 2.5 mg every 72 hours</item>
</list>Use with increased monitoring for
                    adverse events.
                  </td>
</tr>
</tbody>
</table>